Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 100 of 135 entries
View as:

Study of Subcutaneous Immunoglobulin in Patients With PID Requiring IgG Replacement Therapy

Phase: N/A Priority: Normal
NCT ID: NCT00419341 Org: User:
Start: 11/30/06 End: 10/31/08 Due: 10/31/09

An Open Enrollment Study of Factor XIII Concentrate in Subjects With Congenital Factor XIII Deficiency

Phase: N/A Priority: Normal
NCT ID: NCT00945906 Org: User:
Start: 09/30/09 End: 08/31/11 Due: 08/31/12

Long-term Follow-up Study of Male Adults With Hemophilia B Previously Treated With Etranacogene Dezaparvovec (CSL222)

Phase: N/A Priority: Normal
NCT ID: NCT05962398 Org: User:
Start: 08/30/23 End: 03/23/35 Due: 03/23/36

Human Fibrinogen - Pharmacokinetics

Phase: N/A Priority: Normal
NCT ID: NCT00496262 Org: User:
Start: 07/31/07 End: 05/31/08 Due: 05/31/09

CSL200 Gene Therapy in Adults With Severe Sickle Cell Disease

Phase: N/A Priority: Normal
NCT ID: NCT04091737 Org: User:
Start: 10/02/19 End: 05/05/21 Due: 05/05/22

Phase IIB Dose Ranging Study in Subjects With Moderate to Severe Rheumatoid Arthritis

Phase: N/A Priority: Normal
NCT ID: NCT02015520 Org: User:
Start: 06/30/12 End: 06/30/15 Due: 06/30/16

Study of a pd vWF/FVIII, Biostate®, in Subjects With Haemophilia A

Phase: N/A Priority: Normal
NCT ID: NCT00879541 Org: User:
Start: 02/28/09 End: 10/31/10 Due: 10/31/11

A Clinical Study to Test the Efficacy and Safety of CSL312 on Catheter-associated Blood Clot Formation in Subjects With Cancer Who Receive Chemotherapy Through a PICC Line

Phase: N/A Priority: Normal
NCT ID: NCT04281524 Org: User:
Start: 03/31/20 End: 10/31/21 Due: 10/31/22

Safety of Single Doses of CSL889 in Adult Patients With Sickle Cell Disease

Phase: N/A Priority: Normal
NCT ID: NCT04285827 Org: User:
Start: 05/20/21 End: 07/24/23 Due: 07/24/24

Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate

Phase: N/A Priority: Normal
NCT ID: NCT01373151 Org: User:
Start: 06/30/11 End: 06/30/15 Due: 06/30/16

A Study of the Use of Factor XIII Concentrate in Patients With Inherited FXIII Deficiency

Phase: N/A Priority: Normal
NCT ID: NCT00883090 Org: User:
Start: 05/31/09 End: 04/30/10 Due: 04/30/11

Efficacy and Safety of CSL222 (Etranacogene Dezaparvovec) Gene Therapy in Adults With Hemophilia B With Pretreatment Adeno-associated Virus Serotype 5 (AAV5) Neutralizing Antibodies (Nabs)

Phase: N/A Priority: Normal
NCT ID: NCT06003387 Org: User:
Start: 01/30/24 End: 10/04/28 Due: 10/04/29

Phase 3 Study of Fibrinogen Concentrate (CSL511) in Subjects With Pseudomyxoma Peritonei Undergoing Cytoreductive Surgery

Phase: N/A Priority: Normal
NCT ID: NCT06617897 Org: User:
Start: 10/01/24 End: 10/30/26 Due: 10/30/27

Respreeza® Self-administration and Learning Program (AmAREtTI Study)

Phase: N/A Priority: Normal
NCT ID: NCT04262284 Org: User:
Start: 10/18/19 End: 05/06/24 Due: 05/06/25

A Study to Assess the Pharmacokinetics and Safety of CSL312 in Healthy Japanese and Caucasian Adults

Phase: N/A Priority: Normal
NCT ID: NCT04580654 Org: User:
Start: 10/29/20 End: 05/07/21 Due: 05/07/22

A Safety and Pharmacokinetics Study of a Recombinant Fusion Protein Linking Coagulation Factor VIIa With Albumin (rVIIa-FP) in Healthy Male Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT01542619 Org: User:
Start: 03/31/12 End: 07/31/12 Due: 07/31/13

First-In-Human Study To Evaluate The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Escalating Single And Multiple Doses Of CSL040 In Healthy Subjects

Phase: N/A Priority: Normal
NCT ID: NCT05937581 Org: User:
Start: 09/28/23 End: 04/30/25 Due: 04/30/26

Double-blind, Randomized, Placebo-controlled Study Evaluating Efficacy and Safety of IgPro20 in Post-COVID-19 POTS

Phase: N/A Priority: Normal
NCT ID: NCT06524739 Org: User:
Start: 08/28/24 End: 09/24/27 Due: 09/24/28

Register of Patients With haEmophilia A tReated With Afstyla®

Phase: N/A Priority: Normal
NCT ID: NCT04675541 Org: User:
Start: 09/24/18 End: 12/31/24 Due: 12/31/25

A Study to Evaluate the Clinical Pharmacology and Safety of C1-esterase Inhibitor Administered by the Subcutaneous Route

Phase: N/A Priority: Normal
NCT ID: NCT01576523 Org: User:
Start: 04/30/12 End: 12/31/12 Due: 12/31/13

Treatment With CSL312 in Adults With Coronavirus Disease 2019 (COVID-19)

Phase: N/A Priority: Normal
NCT ID: NCT04409509 Org: User:
Start: 07/01/20 End: 01/12/21 Due: 01/12/22

Observational Study of Prophylaxis and Treatment of Acute Perioperative Bleeding With Beriplex® P/N (Probe Study)

Phase: N/A Priority: Normal
NCT ID: NCT01053169 Org: User:
Start: 05/31/10 End: 01/31/12 Due: 01/31/13

Safety, Efficacy and Pharmacokinetics of ALD518 in Patients With Non-Small Cell Lung Cancer-related Fatigue and Cachexia

Phase: N/A Priority: Normal
NCT ID: NCT00866970 Org: User:
Start: 09/30/08 End: 12/31/09 Due: 12/31/10

A Safety and Efficacy Extension Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Patients With Hemophilia B

Phase: N/A Priority: Normal
NCT ID: NCT02053792 Org: User:
Start: 02/06/14 End: 06/02/21 Due: 06/02/22

Study of Subcutaneous Immune Globulin in Patients Requiring IgG Replacement Therapy (Japan Study)

Phase: N/A Priority: Normal
NCT ID: NCT01199705 Org: User:
Start: 09/30/10 End: 11/30/11 Due: 11/30/12